manilatimes4m
Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024
Sales growth driven by continued strong performance from Entresto (+31% cc), Cosentyx (+25% cc), Kesimpta (+49% cc), Kisqali (+49% cc), Pluvicto (+42% cc) and Leqvio (+114% cc) Core operating income ...
Bluewin16m
Pharma Novartis grows significantly in the final quarter
Novartis increased sales by 15 percent to USD 13.2 billion in the fourth quarter of 2024. Profit rose by 7 percent to USD 2.8 billion, as the pharmaceutical company announced on Friday.
EMEA Morning Briefing: Markets Focus on Economic Data, Earnings
The Bureau of Economic Analysis will release the personal consumption expenditures, or PCE, price index for December on Friday at 8:30 a.m. ET, as part of its personal income and outlays report. Gold ...
Novartis beats consensus on Q4 earnings
Japan is considering offering support for a $44 billion gas pipeline in Alaska as it seeks to court U.S. President Donald ...
Novartis, MSN Pharma agree to dismiss Kisqali patent lawsuit
Novartis (NYSE:NVS) and MSN Pharmaceuticals have reached agreement in a Delaware federal court to dismiss patent litigation ...
AbbVie Vs. Novartis: Which Has The Technical Edge Before Q4 Earnings?
AbbVie and Novartis to report Q4 earnings. AbbVie in stagnating trend, Novartis bullish. Breakdown of technical charts. Novartis has advantage, investors watch for post-earnings movement.
Novartis's SWOT analysis: pharma giant's stock faces pipeline and pricing pressures
Novartis AG (NYSE:NVS), a global healthcare company valued at over $206 billion, has undergone significant transformation in recent years, focusing its efforts on becoming a pure-play pharmaceutical ...
American Association of Individual Investors1d
Why Coherus BioSciences, Inc.’s (CHRS) Stock Is Up 10.66%
Coherus BioSciences, Inc.’s CHRS share price has surged by 10.66%, which has investors questioning if this is right time to sell.
JD Supra1d
Federal Circuit Highlights the Importance of Separating Claim Construction and Infringement Analysis When Dealing with After-Arising Technology
Novartis Pharmaceuticals Corporation v. Torrent Pharma Inc., No. 23-2218 (Fed. Cir. 2025) — On January 10, 2025, the Federal Circuit reversed ...
Novartis Expected to Post Higher Profit, Sales -- Earnings Preview
SALES FORECAST: Novartis's sales are forecast at $12.78 billion, according to analysts' estimates compiled by Visible Alpha. This compares with $11.42 billion the year before. Shares rose 5.1% over ...
FiercePharma1d
Amid more drug-price scrutiny, biopharma companies largely keep their January hikes in check
As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...
IPWatchdog1d
An Enablement Defense is Disabled by the Federal Circuit
In Novartis Pharms. Corp. v. Torrent Pharma Inc., the U. S. Court of Appeals for the Federal Circuit shut down efforts to market a generic version of the heart disease drug ENTRESTO which is sold ...